2.65
2.65 (0%)
As of Apr 02, 2024
Kinnate Biopharma Inc. [KNTE]
Source:
Company Overview
We are a clinical stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products that are designed to address significant unmet need. Our Kinnate Discovery Engine, which starts with the identification of an unmet need among validated oncogenic drivers, utilizes our deep expertise in medicinal chemistry and the tailored ecosystems of our partners to develop our targeted therapies.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | 8582994699 |
| Industry | manufacturing |
| CEO | Nima Farzan |
| Website | www.kinnate.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-121.2 |
| Net Income | $-112.6 |
| Net Cash | $2 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -49.8% |
| Profit as % of Stockholder Equity | -70.7% |
Management Effectiveness
| Return on Equity | -70.7% |
| Return on Assets | -64.9% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $173.6 |
| Total Liabilities | $14.3 |
| Operating Cash Flow | $-100 |
| Investing Cash Flow | $109.9 |
| Financing Cash Flow | $-7.8 |
